AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05767632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference first dose)
Description: 1 tablet Vesicare contains Solifenacine succinate 5 mg \& 1 tablet Betmiga contains Mirabegron 50 mg orally administrated followed by 240 ml of water
Study NCT05767632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirfenacin MR (Solifenacin Succinate 5 mg & Mirabegron 50 mg) (Test)
Description: 1 tablet Mirfenacin MR contains Solifenacine succinate 5 mg \& Mirabegron 50 mg orally administrated followed by 240 ml of water
Study NCT05767632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vesicare (Solifenacin Succinate 5 mg) & Betmiga (Mirabegron 50 mg) (Reference second dose)
Description: 1 tablet Vesicare contains Solifenacine succinate 5 mg \& 1 tablet Betmiga contains Mirabegron 50 mg orally administrated followed by 240 ml of water
Study NCT05543512 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Algorithm to diagnose food allergens
Description: An algorithm to diagnose food allergens that will drive diet intervention assignment for those in the active arm. Subjects randomized to this group will receive a diet assignment based on results of the algorithm.
Study NCT05543512 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham diet
Description: Sham diet developed via selecting a random number of foods from a random list of the potential eliminated foods.
Study NCT03877627 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic and Peritoneal Lymphadenectomy
Description: Patients in arm 2 will be randomized to undergo pelvic and peritoneal lymphadenectomy to treat their endometrial carcinoma.
Study NCT05067738 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: same day discharge
Description: same day discharge
Study NCT06224842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone liposome 16 and azacitidine
Description: The mitoxantrone liposome will be intravenous infused at a dose of 16mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
Study NCT06224842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone liposome 18 and azacitidine
Description: The mitoxantrone liposome will be intravenous infused at a dose of 18mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
Study NCT06224842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone liposome 20 and azacitidine
Description: The mitoxantrone liposome will be intravenous infused at a dose of 20mg/m\^2 on day1 , combined with subcutaneous injection of azacitidine at a dose of 75 mg/m\^2 on days 1-7, with each cycle lasting 4 weeks (28 days).
Study NCT05511142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classic Peyton's Four-Step Approach
Description: Instructor demonstrated endotracheal intubation and mask ventilation procedural skills directly to the preclinical students, followed by direct hands-on practice using manequin, ended with giving feedback to the students
Study NCT05511142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Peyton's Four-Step Approach
Description: Video tutorial of endotracheal intubation and mask ventilation were given to the students without explanation, followed by video tutorial making using manequin (without instructor) by the students which will be uploaded to Youtube
Study NCT06551480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biometry
Description: Only one eye from each patient will be included in the study. All subjects and patients included in the study will undergo biometric measurements with both devices (IOL master 500 and VCSEL based swept source optical biometry).
Study NCT05159895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-DZD9008
Description: Each subject will receive a total of 100 mg DZD9008 oral suspension containing approximately 1 μCi of \[14C\] as a single administration
Study NCT05673642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release Techniques
Description: Myofascial Release Technique (MFR), which we will apply to the muscles we choose related to the facial system connection
Study NCT06377397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: In experimental arm, intravenous antibiotics as per the written down empirical antibody policy of the unit will be administered selectively to those newborn infants who later develop clinical signs of sepsis according to a predefined repertory of clinical signs.~In active comparator arm, intravenous antibiotics as per the written down empirical antibody policy of the unit will be administered pre-emptively to all newborn infants from enrollment even if they do not have any clinical signs of sepsis at enrollment
Study NCT06377397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics
Description: In experimental arm, intravenous antibiotics as per the written down empirical antibody policy of the unit will be administered selectively to those newborn infants who later develop clinical signs of sepsis according to a predefined repertory of clinical signs.~In active comparator arm, intravenous antibiotics as per the written down empirical antibody policy of the unit will be administered pre-emptively to all newborn infants from enrollment even if they do not have any clinical signs of sepsis at enrollment
Study NCT05422781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-3000
Description: ITI-3000 is a DNA vaccine (L-H LT S220A) which contains sequences for both LAMP1 and LTS220A, the truncated form of the LT antigen of MCPyV with a detoxifying serine to alanine mutation at position 220
Study NCT04931056 — intervention group
Intervention type: DEVICE
Intervention: Titanium Facial Plates
Description: The Facial Plating System provides a comprehensive titanium fixation solution for maxillofacial surgery procedures. More than twenty-five different plating options in two systems, the 1.5 mm and 2.0 mm with a variety of instruments, and high torque screws, including meshes, are part of this system. Plates and screws are made of commercially pure titanium per ASTM F-67, Titanium 6Al 4V Alloy per ASTM F-136.
Study NCT04931056 — intervention group
Intervention type: DEVICE
Intervention: Titanium Mandibular Plates
Description: The Mandibular Plating System provides a comprehensive titanium fixation solution for mandibular surgical procedures. Several plating options, a variety of instruments, and high torque screws with various plate shapes are part of this system.~Plates in the Mandibular Plating System have profiles of various thicknesses. Screws are available in self-tapping, locking and non-locking varieties, and in various sizes between 2.0 mm and 2.3 mm in diameter, and 5 mm to 18 mm in length.
Study NCT04931056 — intervention group
Intervention type: DEVICE
Intervention: Add-on Condyle
Description: The Add-On Condyle is intended to be implanted in the human jaw to replace the mandibular condyle to functionally reconstruct the temporomandibular joint on a temporary basis for patients undergoing ablative tumor surgery requiring the removal of the native mandibular condyle. This device is not for permanent implantation, traumatic injuries, or for treatment of temporomandibular joint disease.
Study NCT04931056 — intervention group
Intervention type: DEVICE
Intervention: HTR-PEKK
Description: The HTR-PEKK implants are fabricated from polyether-ketone-ketone (PEKK) via selective laser sintering (SLS), a 3D manufacturing technique. The laser sintering machine builds the implant in layers as dictated from a stereolithographic (STL) file of the approved implant. The HTR-PEKK implants are designed individually for each patient to replace bony voids in the facial anatomy using a patient's own CT imaging data. The implant is made to fill an existing or planned void (where appropriate) using computer-aided design technology for anatomy enhancement, correction of trauma injuries, and/or to correct congenital defects in the craniofacial bone.
Study NCT05506202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individual basic body awareness therapy
Description: Basic Body Awareness Therapy (BBAT) is a physiotherapeutic intervention directed toward patients' functional movement quality. The development of BBAT was based on the hypothesis of persons' lacking contact with and lacking awareness on their own body, with their inner life, external environment and in the relation to other persons. Thus, it leads to dysfunctional movement, pain and other body functions. BBAT focus on multi-perspective within a person including physical, physiological, psycho-social-cultural and existential perspectives. It directs patients to be aware, guides patients to have mental contact with their body, monitors internal sensations and external environment, and thus, to enhance the self-regulated behavior and positive emotional state.
Study NCT05506202 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory physiotherapy interventions
Description: Comprehensive physical and psycho-social assessment and treatments are included. Both basic and advanced respiratory physiotherapy interventions, including respiratory muscles training, breathing techniques, bronchial hygiene maintenance, assisting in non-invasive ventilation therapy and oxygen therapy titration, are provided according to assessment findings.
Study NCT05506202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory physiotherapy interventions
Description: Comprehensive physical and psycho-social assessment and treatments are included. Both basic and advanced respiratory physiotherapy interventions, including respiratory muscles training, breathing techniques, bronchial hygiene maintenance, assisting in non-invasive ventilation therapy and oxygen therapy titration, are provided according to assessment findings.
Study NCT05620576 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3857210
Description: Administered orally
Study NCT05620576 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT06076694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2198
Description: Group A, TNP-2198 capsules 400mg(4 capsules),BID, 14days Group B, TNP-2198 capsules 600mg(6 capsules),BID, 14days Group C , TNP-2198 capsules 600mg(6 capsules),TID, 14days Group D, TNP-2198 capsules 600mg(6 capsules),TID, 7days
Study NCT06076694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole Sodium
Description: Group A,Group B,Control group: Rabeprazole sodium enteric-coated tablets 20 mg, BID, 14days Group C :Rabeprazole sodium enteric-coated tablets 20 mg, TID, 14 days Group D : Rabeprazole sodium enteric-coated tablets 20 mg, TID, 7 days
Study NCT06076694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole Sodium
Description: Group A,Group B,Control group: Rabeprazole sodium enteric-coated tablets 20 mg, BID, 14days Group C :Rabeprazole sodium enteric-coated tablets 20 mg, TID, 14 days Group D : Rabeprazole sodium enteric-coated tablets 20 mg, TID, 7 days
Study NCT06076694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Group A,Group B,Control group: Amoxicillin capsules 1g, BID, 14days Group D : Amoxicillin capsules 1g, TID, 7 days
Study NCT06076694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Group A,Group B,Control group: Amoxicillin capsules 1g, BID, 14days Group D : Amoxicillin capsules 1g, TID, 7 days
Study NCT06438042 — intervention group
Intervention type: DEVICE
Intervention: Use of a powered low air pressure motorised therapeutic mattress that combines the motorised and static technologies
Description: Patients with a high risk of pressure injury, without pressure injury, lying more than 20 hours a day, will ly a on a XTECH®25 mattress
Study NCT05250024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UHMWP Cranioplasty
Description: patient specific cranial implant
Study NCT05250024 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PEEK Cranioplasty
Description: patient specific cranial implant
Study NCT04914910 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minimed 780G insulin pump
Description: This will be a 14-week, open-label, randomised, parallel-group, controlled trial comparing the efficacy of an AHCL system (MiniMed 780G, Medtronic Diabetes, Northridge, CA) with usual care (i.e., a person's usual insulin pump and CGM/isCGM system). After the 14-week trial period, the control group switches to treatment with the MiniMed 780G system. The intervention group continues with the MiniMed 780G system. Both groups are monitored for another 14 weeks.
Study NCT04914910 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Minimed 780G insulin pump
Description: This will be a 14-week, open-label, randomised, parallel-group, controlled trial comparing the efficacy of an AHCL system (MiniMed 780G, Medtronic Diabetes, Northridge, CA) with usual care (i.e., a person's usual insulin pump and CGM/isCGM system). After the 14-week trial period, the control group switches to treatment with the MiniMed 780G system. The intervention group continues with the MiniMed 780G system. Both groups are monitored for another 14 weeks.
Study NCT05381584 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopy
Description: laparoscopy will be done under anesthesia for management for cases with blind vagina
Study NCT05381584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopy
Description: laparoscopy will be done under anesthesia for management for cases with blind vagina
Study NCT05408416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preoperative group and intraoperative group
Description: ranibizumab injection (0.5mg/0.05ml) 3-5 days before vitrectomy or ranibizumab injection (0.5mg/0.05ml) at the end of vitrectomy
Study NCT04975100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarcosine and SSRI
Description: Patients in the test group will get Sarcosine 500 mg capsules once daily as an add-on to ongoing SSRI treatment
Study NCT05408416 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preoperative group and intraoperative group
Description: ranibizumab injection (0.5mg/0.05ml) 3-5 days before vitrectomy or ranibizumab injection (0.5mg/0.05ml) at the end of vitrectomy
Study NCT04975100 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo and SSRI
Description: Patients in the control group will get identical-looking capsules containing placebo in addition to SSRI at an once daily dose
Study NCT05437432 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VITA AMBRIA
Description: 25 onlay restroations will be fabricated from Vita-ambria glass ceramic press system.
Study NCT05437432 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IPS e.max press
Description: 25 onlay restroations will be fabricated from IPS e.max glass ceramic press system.
Study NCT04960293 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uterine artery embolization using spherical gelfoam
Description: Uterine artery embolization is performed using spherical gelfoam. All other processes are same.
Study NCT04960293 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: uterine artery embolization using tri-acryl gelatin microsphere
Description: Uterine artery embolization is performed using tris-acryl gelatin microsphere. All other processes are same.
Study NCT05677620 — intervention group
Intervention type: RADIATION
Intervention: Pharyngeal Computed Tomography
Description: To assess the presence of a possible level/level of collapse, a pharyngeal CT with cephalometry will be performed, and a standard classification system, VOTE, will be used. After obtaining said CT, the dentist will place the recording in MCP and perform a new CT scan of the pharynx with cephalometry and with the MCP recording set intraorally to assess whether this position reduces or eliminates the collapse from UA.
Study NCT05677620 — intervention group
Intervention type: DRUG
Intervention: Drug-Induced Sleep Endoscopy (Propofol)
Description: The DISE technique will be performed by an otorhinolaryngologist (ENT) with a nasopharyngoscope in a operating room. This technique is complemented with bite registration (MCP). Artificial sleep will be induced by intravenous administration of propofol through an infusion system controlled by an anesthesiologist (2.0-3.0 mcg/mL). The following variables will be continuously monitored: electrocardiography, oxygen saturation, and bispectral index (BIS). In this phase of the DISE, the upper airways will be evaluated during sleep with the MCP positioned intra-orally.
Study NCT06257381 — intervention group
Intervention type: OTHER
Intervention: VO2max
Description: Overall design 16 non-smoking individuals with COPD and 16 controls (non-smokers) matched for age and sex on a group level will be included in the study. The study consists of two study days. Separation between the study days are at least 48 hours and maximum 10 days.~Before entering the study: Informed written and oral consent.~Study day 1: Medical examination, full lung function testing (dynamic spirometry, whole-body plethysmography, diffusion capacity) followed by a maximal oxygen consumption test (VO2peak), VO2-verification bout and VO2kinetic test (duration 3h).~Study day 2: Participants will undergo a maximal oxygen consumption test (VO2peak), VO2-verification bout and VO2kinetic test (duration 1,5h).
Study NCT05269095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia only
Description: Patients will receive spinal anesthesia with 2-3 ml 0.5% (10-15 mg) hyperbaric bupivacaine plus 25 ug fentanyl at the L3/4 interspaces.
Study NCT05269095 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia and ultrasound-guided Genicular nerves block
Description: Patients will receive16 ml bupivacaine 0025% will be administered, and4 ml of this solution will be placed at each of the 4 target nerves.
Study NCT05269095 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Adductor Canal block (ACB) technique with infiltration of the interspace between popliteal artery and the capsule of posterior knee block ('PACK)
Description: Adductor Canal block (ACB) technique will be performed using 16 ml bupivacaine 0025% As regarding the Popliteal artery and the capsule of posterior knee block ('PACK), it will be performed Using 16 ml bupivacaine 0.25%
Study NCT05040074 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SQ-Kyrin Transcatheter Edge-to-Edge Valve Repair System
Description: Transesophageal echocardiography-guided, implantable mitral valve clip repair system
Study NCT05406102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Patients received an initial dose of 0.1mg/kg of remimazolam (add to 0.05 mg/kg top-ups doses to a total of up to five times within 15minutes).
Study NCT05406102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol group
Description: Patients received an initial dose of 1.5mg/kg of propofol(add to 0.5 mg/kg top-ups doses to a total of up to five times within 15minutes).
Study NCT05151757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A standard image training set
Description: The standard image training set will consist of about 50 normal optic nerve images of people without glaucoma and about 50 images of people with glaucoma. Training is done in 3 modules.
Study NCT05121376 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose 1 of BMN 331
Description: BMN 331 AAV Gene Therapy
Study NCT05121376 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose 2 of BMN 331
Description: BMN 331 AAV Gene Therapy
Study NCT05121376 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose 3 of BMN 331
Description: BMN 331 AAV Gene Therapy
Study NCT04896476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EchoMark
Description: The EchoMark is to be secured a minimum of 3 cm away from the anastomosis.
Study NCT05107622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMUD+Probiotic
Description: Full-mouth ultrasonic periodontal debridement associated with administration of probiotic formulation (Lactobacillus paracasei 28.4) twice a day for 30 days.
Study NCT05107622 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: FMUD+Placebo
Description: Full-mouth ultrasonic periodontal debridement associated with administration of placebo formulation twice a day for 30 days.
Study NCT06224764 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Mother and Father questionnaires
Description: Mother and Father questionnaires (on paper or by phone) and data collectionon newborns weighing less than 2 kilos (at discharge from birth to 11 months)
Study NCT05677620 — intervention group
Intervention type: DEVICE
Intervention: Mandibular Advancement Device
Description: A duo-block, titratable, and customized MAD (NOA®; Orthoapnea) will be fitted for each patient who starts treatment with MAD. The MAD consists of two CAD/CAM polyamide intraoral devices (one for the upper and one for the lower arch). The adaptation period takes place over one month. After this adaptation, patients will undergo a new PSG using MAD.
Study NCT05121376 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose 4 of BMN 331
Description: BMN 331 AAV Gene Therapy
Study NCT05121376 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose 5 of BMN 331
Description: BMN 331 AAV Gene Therapy
Study NCT05121376 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose 6 of BMN 331
Description: BMN 331 AAV Gene Therapy
Study NCT05121376 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Dose 7 of BMN 331
Description: BMN 331 AAV Gene Therapy
Study NCT04945044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computed adenoma detection system (CADe)
Description: This is a computed system that helps the endoscopist to increase the detection of colorectal polyps